Ogeda S.A.
https://www.ogeda.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ogeda S.A.
2023 Will Be A Year Of Partnerships And Acquisitions For Astellas
Astellas’ Mike Luther sees 2023 as a year of growing assets and creating partnerships. The global head of search and evaluation business development told In Vivo about the company's focus on gene and cell therapy and what he thinks makes for a successful business deal.
Astellas Plots US Portfolio Expansion
US president Mark Reisenauer talked to Scrip about the company's next growth drivers, including fezolinetant for vasomotor symptoms and zolbetuximab for gastric cancer.
Menopause Drug A Priority For Astellas
The Japanese group has used a priority review voucher for fezolinetant to move further ahead of Bayer’s elinzanetant as it seeks regulatory approval to bring a non-hormonal therapy for menopausal symptoms such as hot flashes and night sweats to market.
Astellas’s Long-Term Safety Data Could Boost Fezolinetant’s Approval Chances
With a pair of successful Phase III pivotal studies in hand, the Japanese pharma reports that its nonhormonal hot flash/night sweats candidate demonstrated safety and tolerability over 52 weeks.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Technologies
- Other Names / Subsidiaries
-
- Euroscreen
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice